Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

194.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin... 
Via Talk Markets
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR)  
Via Benzinga
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
From BeiGene, Ltd.
Via Business Wire
Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
Via Benzinga
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
From BeiGene
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Latest Analyst Ratings for BeiGene
Via Benzinga
Analyst Expectations for BeiGene's Future
Via Benzinga
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS). 
Via Benzinga
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
From BeiGene, Ltd.
Via Business Wire
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
From BeiGene, Ltd.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From BeiGene
Via Business Wire
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023
Via Benzinga
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
From BeiGene, Ltd.
Via Business Wire
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a  
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
From BeiGene
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.